NCT04575389

Brief Summary

This study will be undertaken to evaluate the association of serum uric acid (SUA) level with metabolic risk factors in patients with type 2 diabetes and their relation to eGFR status

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2020

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 29, 2020

Completed
2 days until next milestone

Study Start

First participant enrolled

October 1, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 5, 2020

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2021

Completed
Last Updated

October 5, 2020

Status Verified

September 1, 2020

Enrollment Period

1 year

First QC Date

September 29, 2020

Last Update Submit

September 29, 2020

Conditions

Metabolic Syndrome

Outcome Measures

Primary Outcomes (1)

  • the association of serum uric acid (SUA) level with metabolic risk factors in patients with type 2 diabetes

    the incidence of hypertension, a component of metabolic syndrome, is significantly higher among patients with hyperuricemia. Waist circumference and serum triglycerides are higher, whereas serum high-density lipoprotein level is lower in patients with higher SUA level.

    baseline

Interventions

Serum uric acid levels ,HBA1C , fasting plasma glucose ,lipid profile , creatinine levelDIAGNOSTIC_TEST

diagnostic tests

Eligibility Criteria

Age30 Years - 90 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patient will be collected randomly from outpatient clinics of diabetic center of assiut univeristy

You may qualify if:

  • type 2 diabetic patient

You may not qualify if:

  • patients with type 1 diabetes
  • gestational diabetes
  • patients with drug affecting uric acid levels
  • secondary diabetes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (10)

  • Bellows JG. Editorial: Continuing education in ophthalmology. Ann Ophthalmol. 1976 Jun;8(6):649. No abstract available.

    PMID: 937945BACKGROUND

  • Fontelo P, Liu F. Finding translational science publications in MEDLINE/PubMed with translational science filters. Clin Transl Sci. 2011 Dec;4(6):455-9. doi: 10.1111/j.1752-8062.2011.00320.x. Epub 2011 Nov 7.

    PMID: 22212228BACKGROUND

  • Pozas E, Pascual M, Nguyen Ba-Charvet KT, Guijarro P, Sotelo C, Chedotal A, Del Rio JA, Soriano E. Age-dependent effects of secreted Semaphorins 3A, 3F, and 3E on developing hippocampal axons: in vitro effects and phenotype of Semaphorin 3A (-/-) mice. Mol Cell Neurosci. 2001 Jul;18(1):26-43. doi: 10.1006/mcne.2001.0999.

    PMID: 11461151BACKGROUND

  • Wang XR, Robinson KM, Carter-Harris L. Prevalence of chronic illnesses and characteristics of chronically ill informal caregivers of persons with dementia. Age Ageing. 2014 Jan;43(1):137-41. doi: 10.1093/ageing/aft142. Epub 2013 Sep 26.

    PMID: 24072413BACKGROUND

  • Turner AJ, Hick PE. Inhibition of aldehyde reductase by acidic metabolites of the biogenic amines. Biochem Pharmacol. 1975 Sep 15;24(18):1731-3. doi: 10.1016/0006-2952(75)90016-7. No abstract available.

    PMID: 16BACKGROUND

  • Kunkler I, Jack W, Prescott R, Williams L, King C. Postoperative breast irradiation: new trials needed in older patients. J Clin Oncol. 2003 May 1;21(9):1893; author reply 1893-4. doi: 10.1200/jco.2003.99.239. No abstract available.

    PMID: 12721273BACKGROUND

  • Woods DJ. Conceptualizing depression and its treatment: comparison of psychoanalytic and behavioral approaches. Psychol Rep. 1975 Dec;37(3 PT 2):1271-8. doi: 10.2466/pr0.1975.37.3f.1271. No abstract available.

    PMID: 1823BACKGROUND

  • Dupuy B, Mounier J, Blanquet P. [Some comments on the biological properties of calcitonin: an eventual new therapeutic utilization (author's transl)]. Ann Endocrinol (Paris). 1977 Jul-Aug;38(4):323-6. French.

    PMID: 561566BACKGROUND

  • Fritsch P, Honigsmann H, Jaschke E, Wolff K. [Photochemotherapy of psoriasis: increasing its effectiveness with an oral aromatic retinoid (clinical results in 134 patients) (author's transl)]. Dtsch Med Wochenschr. 1978 Nov 3;103(44):1731-6. doi: 10.1055/s-0028-1129333. German.

    PMID: 361362BACKGROUND

  • Bundgaard H. Polymerization of penicillins: kinetics and mechanism of di- and polymerization of ampicillin in aqueous solution. Acta Pharm Suec. 1976;13(1):9-26. No abstract available.

    PMID: 3942BACKGROUND

MeSH Terms

Conditions

Metabolic Syndrome

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Central Study Contacts

esraa tarek, master

CONTACT

01004590619esraatarek062@gmail.com

salah abdelazeem, professor

CONTACT

01064559917argoons@yahoo.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

September 29, 2020

First Posted

October 5, 2020

Study Start

October 1, 2020

Primary Completion

October 1, 2021

Study Completion

November 1, 2021

Last Updated

October 5, 2020

Record last verified: 2020-09